 |
| SK바이오사이언스 (사진 = SK바이오사이언스 홈페이지) |
[Alpha Biz=(Chicago) Reporter Paul Lee] SK Bioscience has announced an investment plan of about 2.4 trillion won over the next five years to become a global leader in vaccines and bios. It is about five times the amount invested from 2018 to last year.
Ahn Jae-yong, president of SK Bioscience, held a press conference at the Korea Press Center in Jung-gu, Seoul on the morning of the 28th and said, "Five years from now is the time of active investment that will determine the future of SK Bioscience," adding, "We will grow quickly and systematically."
Detailed strategies include △ Expansion of overseas business △ Strengthening vaccine business △ Securing new platform △ Endemic response portfolio and infrastructure expansion.
As the possibility of annual vaccination increases with the COVID-19 Endemic, it will strengthen internal stability to cope with new pandemics along with existing infectious diseases.
SK Bioscience is checking the preventive effect against new mutated viruses such as BN.1 and XBB of Skycobyone, the first COVID-19 vaccine in Korea. It plans to secure data on mutation prevention as early as the first half of the year.
In order to secure competitiveness in overseas markets, the company plans to expand its regional expansion and expand its CDMO (Consignment Development Production) business.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
